MA50522B1 - Nanoparticules lipidiques pour l'administration d'un arn modifié codant pour un polypeptide vegf-a - Google Patents

Nanoparticules lipidiques pour l'administration d'un arn modifié codant pour un polypeptide vegf-a

Info

Publication number
MA50522B1
MA50522B1 MA50522A MA50522A MA50522B1 MA 50522 B1 MA50522 B1 MA 50522B1 MA 50522 A MA50522 A MA 50522A MA 50522 A MA50522 A MA 50522A MA 50522 B1 MA50522 B1 MA 50522B1
Authority
MA
Morocco
Prior art keywords
vegf
polypeptide
modified rna
rna encoding
delivery
Prior art date
Application number
MA50522A
Other languages
English (en)
Other versions
MA50522A (fr
Inventor
Kerry Benenato
Kenny Hansson
Maria Wågberg
Annika Pålsson
Regina Fritsche-Danielson
Original Assignee
Astrazeneca Ab 151 85 Soedertaelje
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab 151 85 Soedertaelje filed Critical Astrazeneca Ab 151 85 Soedertaelje
Publication of MA50522A publication Critical patent/MA50522A/fr
Publication of MA50522B1 publication Critical patent/MA50522B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

L'invention concerne des nanoparticules comprenant un constituant lipidique et un arn modifié codant pour un polypeptide vegf-a. Des aspects de l'invention concernent en outre des utilisations de nanoparticules comprenant un constituant lipidique et un arn modifié codant pour un polypeptide vegf-a, pour améliorer la cicatrisation des plaies chez un sujet.
MA50522A 2017-10-31 2018-10-31 Nanoparticules lipidiques pour l'administration d'un arn modifié codant pour un polypeptide vegf-a MA50522B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579671P 2017-10-31 2017-10-31
PCT/US2018/058541 WO2019089818A1 (fr) 2017-10-31 2018-10-31 Nanoparticules lipidiques pour l'administration d'un arn modifié codant pour un polypeptide vegf-a

Publications (2)

Publication Number Publication Date
MA50522A MA50522A (fr) 2021-05-26
MA50522B1 true MA50522B1 (fr) 2022-09-30

Family

ID=64557129

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50522A MA50522B1 (fr) 2017-10-31 2018-10-31 Nanoparticules lipidiques pour l'administration d'un arn modifié codant pour un polypeptide vegf-a

Country Status (22)

Country Link
US (1) US11696892B2 (fr)
EP (1) EP3703658B1 (fr)
JP (2) JP7308000B2 (fr)
KR (1) KR20200081420A (fr)
CN (1) CN111356444A (fr)
AU (1) AU2018358049A1 (fr)
BR (1) BR112020008404A2 (fr)
CA (1) CA3080592A1 (fr)
DK (1) DK3703658T3 (fr)
EA (1) EA202090919A1 (fr)
ES (1) ES2922462T3 (fr)
HR (1) HRP20220843T1 (fr)
HU (1) HUE059049T2 (fr)
IL (1) IL274230B2 (fr)
LT (1) LT3703658T (fr)
MA (1) MA50522B1 (fr)
PL (1) PL3703658T3 (fr)
PT (1) PT3703658T (fr)
RS (1) RS63389B1 (fr)
SG (1) SG11202003941XA (fr)
SI (1) SI3703658T1 (fr)
WO (1) WO2019089818A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3027221A1 (fr) 2013-07-30 2016-06-08 PhaseRx, Inc. Copolymères séquencés et leur conjugués ou complexes avec des oligonucléotides
WO2016118697A1 (fr) 2015-01-21 2016-07-28 Phaserx, Inc. Procédés, compositions et systèmes permettant l'administration d'agents thérapeutiques et diagnostiques dans des cellules
HUE059127T2 (hu) 2015-10-22 2022-10-28 Modernatx Inc Légúti vírusok elleni vakcinák
PL3464338T3 (pl) 2016-06-07 2021-12-27 Modernatx, Inc. Zmodyfikowany RNA kodujący polipeptydy VEGF, formulacje i zastosowania z nimi związane
EP3562510A4 (fr) 2016-12-30 2021-01-06 Genevant Sciences GmbH Molécules de peg ramifié, compositions et procédés associés
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
EP3668977A4 (fr) 2017-08-18 2021-04-21 Modernatx, Inc. Procédés analytiques par hplc
CN111212905A (zh) 2017-08-18 2020-05-29 摩登纳特斯有限公司 Rna聚合酶变体
MA49922A (fr) 2017-08-18 2021-06-02 Modernatx Inc Procédés pour analyse par clhp
WO2019046809A1 (fr) 2017-08-31 2019-03-07 Modernatx, Inc. Procédés de fabrication de nanoparticules lipidiques
PL3703658T3 (pl) 2017-10-31 2022-08-22 Astrazeneca Ab Nanocząstki lipidowe do dostarczania zmodyfikowanego rna kodującego polipeptyd vegf-a
CN114173826A (zh) * 2019-05-08 2022-03-11 阿斯利康(瑞典)有限公司 使用脂质纳米颗粒用于递送编码vegf-a多肽的经修饰的rna的方法和包含其的药物组合物
AU2020325221A1 (en) * 2019-08-07 2022-03-03 Modernatx, Inc. Compositions and methods for enhanced delivery of agents
WO2021155274A1 (fr) * 2020-01-31 2021-08-05 Modernatx, Inc. Procédés de préparation de nanoparticules lipidiques
CN113185421B (zh) * 2020-11-27 2022-01-25 广州市锐博生物科技有限公司 脂质化合物及其组合物
CN114149337B (zh) * 2021-07-07 2022-04-29 天津键凯科技有限公司 一种用于核酸递送的新型可电离脂质及其lnp组合物
AU2022336209A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
CN113941011A (zh) * 2021-10-15 2022-01-18 浙江汇科泽华生物技术有限公司 一种含可离子化阳离子脂质的纳米脂质体颗粒及制备方法
WO2023073228A1 (fr) 2021-10-29 2023-05-04 CureVac SE Arn circulaire amélioré pour exprimer des protéines thérapeutiques
WO2023144330A1 (fr) 2022-01-28 2023-08-03 CureVac SE Inhibiteurs de facteurs de transcription codés par un acide nucleique
CN114456081A (zh) * 2022-02-15 2022-05-10 浙江汇科泽华生物技术有限公司 一种可离子化脂质及其制备方法和应用
WO2023227608A1 (fr) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Vaccin à base d'acide nucléique codant pour un polypeptide antigénique fimh d'escherichia coli
WO2024037578A1 (fr) * 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition de nanoparticules lipidiques
CN115197431B (zh) * 2022-09-15 2022-11-29 清华大学 脂质偶联完全可降解水溶性聚合物的合成及应用
WO2024089638A1 (fr) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Vaccin à base d'acide nucléique
CN116474120A (zh) * 2023-04-03 2023-07-25 臻赫医药(杭州)有限公司 重编程因子抗衰老mRNA组合物、制备方法及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
JP5705127B2 (ja) 2008-12-03 2015-04-22 アモーサイト インコーポレイテッド 梗塞領域灌流改善組成物および血管損傷修復の方法
JP5971948B2 (ja) 2008-12-04 2016-08-17 クルナ・インコーポレーテッド Ｖｅｇｆに対する天然アンチセンス転写物の抑制による血管内皮増殖因子（ｖｅｇｆ）関連疾患の治療
WO2011069529A1 (fr) 2009-12-09 2011-06-16 Curevac Gmbh Solution contenant du mannose pour la lyophilisation, la transfection et/ou l'injection d'acides nucléiques
WO2012103985A2 (fr) 2010-12-16 2012-08-09 Steve Pascolo Composition pharmaceutique à base d'arn qui comprend un métal alcalin en tant que contre-ion et formulé avec des dications
WO2012138453A1 (fr) 2011-04-03 2012-10-11 The General Hospital Corporation Expression protéique efficace in vivo à l'aide d'arn modifié (mod-arn)
LT2791160T (lt) * 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
US9283287B2 (en) * 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501513B2 (en) * 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US20140275229A1 (en) * 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9663564B2 (en) * 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
EP2971010B1 (fr) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
KR102354389B1 (ko) 2013-08-21 2022-01-20 큐어백 아게 Rna―암호화된 단백질의 발현을 증가시키는 방법
JP6786392B2 (ja) 2014-01-15 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体
EP3247398A4 (fr) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Compositions de nanoparticules lipidiques
ES2910425T3 (es) * 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
PL3464338T3 (pl) 2016-06-07 2021-12-27 Modernatx, Inc. Zmodyfikowany RNA kodujący polipeptydy VEGF, formulacje i zastosowania z nimi związane
WO2018104540A1 (fr) 2016-12-08 2018-06-14 Curevac Ag Arn pour la cicatrisation des plaies
MX2016016339A (es) 2016-12-09 2018-06-08 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V Composicion coadyuvante de un factor de crecimiento y un neuropeptido para acelerar la cicatrizacion de heridas y la repitelizacion de organos.
PL3703658T3 (pl) 2017-10-31 2022-08-22 Astrazeneca Ab Nanocząstki lipidowe do dostarczania zmodyfikowanego rna kodującego polipeptyd vegf-a
US20220226438A1 (en) 2019-05-08 2022-07-21 Astrazeneca Ab Compositions for skin and wounds and methods of use thereof

Also Published As

Publication number Publication date
RS63389B1 (sr) 2022-08-31
US20200338004A1 (en) 2020-10-29
LT3703658T (lt) 2022-07-25
EP3703658A1 (fr) 2020-09-09
MA50522A (fr) 2021-05-26
PT3703658T (pt) 2022-07-18
US11696892B2 (en) 2023-07-11
IL274230B2 (en) 2023-12-01
IL274230B1 (en) 2023-08-01
DK3703658T3 (da) 2022-07-18
JP2023138984A (ja) 2023-10-03
JP2021508434A (ja) 2021-03-11
SG11202003941XA (en) 2020-05-28
BR112020008404A2 (pt) 2020-11-03
WO2019089818A1 (fr) 2019-05-09
AU2018358049A1 (en) 2020-05-21
ES2922462T3 (es) 2022-09-15
CA3080592A1 (fr) 2019-05-09
EA202090919A1 (ru) 2020-09-09
IL274230A (en) 2020-06-30
HRP20220843T1 (hr) 2022-10-14
EP3703658B1 (fr) 2022-05-04
PL3703658T3 (pl) 2022-08-22
SI3703658T1 (sl) 2022-09-30
KR20200081420A (ko) 2020-07-07
HUE059049T2 (hu) 2022-10-28
JP7308000B2 (ja) 2023-07-13
CN111356444A (zh) 2020-06-30

Similar Documents

Publication Publication Date Title
MA50522B1 (fr) Nanoparticules lipidiques pour l'administration d'un arn modifié codant pour un polypeptide vegf-a
NZ718817A (en) Lipid formulations for delivery of messenger rna
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
EP3192526A3 (fr) Exosomes d'administration d'agents biothérapeutiques
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
MX2016004605A (es) Formulaciones de anticuerpos estables acuosas.
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2016007629A3 (fr) Compositions et méthodes d'administration pour traiter les infections, l'inflammation et la sensibilité dentaires, et destinées à être utilisées dans les restaurations dentaires
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
EP4324845A3 (fr) Procédés et composition pharmaceutique pour le traitement et la prévention de cardiomyopathie due à un manque d'énergie
PH12015502102B1 (en) Reducing proinflammatory response
WO2014108846A3 (fr) Composition cosmétique apaisante basée sur de l'acide salicylique
BR112015015864A2 (pt) composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
JP2014058541A5 (fr)
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
EA201591188A1 (ru) Доставка глатирамера ацетата через слизистую оболочку
MX2017009827A (es) Formulacion farmaceutica.
MX2015011927A (es) Reduccion de riesgo de enfermedades autoinmune.
PH12015502037A1 (en) Activating adiponectin by casein hydrolysate
NZ705930A (en) A pharmaceutical composition comprising a solid nanoparticle and at least an antigen for the treatment against an intracellular pathogenic agent
WO2014039074A3 (fr) Compositions thérapeutiques et méthodes associées